CMS, BIO spin Part B data in opposite directions

CMS and the biopharma industry are presenting conflicting explanations for a spike in Medicare Part B premiums and deductibles.

CMS says the increases are “largely due to rising spending on physician-administered drugs” (see “Medicare Part B Premium Spike Could Create Pressure for International Reference Pricing.”).


Read the full 467 word article

User Sign In